Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics, a clinical-stage biopharmaceutical company focused on bifunctional therapies for solid tumors, announced an inducement grant of stock options to a new employee. The grant, approved under Nasdaq listing rules, includes options to purchase 44,175 shares at the closing price of $20.50 per share, vesting over time with continued em…